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Abstract
Purpose: The purpose of this study was to evaluate the efficacy of HDR brachytherapy for primary
or recurrent vaginal cancer.
Methods: Between the years 2000 to 2006, 18 patients with primary or recurrent vaginal cancer
were treated with brachytherapy (HDRB). Six patients had primary vaginal cancer (stage II to IVA)
while 12 were treated for isolated vaginal recurrence (primary cervix = 4, vulva = 1 and
endometrium = 7). Five patients had previous pelvic radiation therapy. All except one patient
received external beam radiation therapy to a median dose of 45 Gy (range 31.2–55.8 Gy). The
HDRB was intracavitary using a vaginal cylinder in 5 patients and interstitial using a modified Syed-
Nesblett template in 13 patients. The dose of interstitial brachytherapy was 18.75 Gy in 5 fractions
delivered twice daily. The median follow-up was 18 months (range 6–66 months).
Results: Complete response (CR) was achieved in all but one patient (94%). Of these 17 patients
achieving a CR, 1 had local recurrence and 3 had systemic recurrence at a median time of 6 months
(range 6–22 months). The 2-year actuarial local control and cause-specific survival for the entire
group were 88% and 82.5%, respectively. In subset analysis, the crude local control was 100% for
primary vaginal cancer, 100% for the group with recurrence without any prior radiation and 67%
for group with recurrence and prior radiation therapy. Two patients had late grade 3 or higher
morbidity (rectovaginal fistula in one patient and chronic vaginal ulcer resulting in bleeding in one
patient). Both these patients had prior radiation therapy.
Conclusion: Our small series suggests that HDRB is efficacious for primary or recurrent vaginal
cancer. Patients treated with primary disease and those with recurrent disease without prior
irradiation have the greatest benefit from HDRB in this setting. The salvage rate for patients with
prior radiation therapy is lower with a higher risk of significant complications. Additional patients
and follow-up are ongoing to determine the long-term efficacy of this approach.
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Background
Primary or recurrent vaginal carcinoma is an uncommon
tumor [1]. The initial tumor volume, tumor extent within
the vagina, histologic type and grade, lymphatic involve-
ment and previous treatment are all important determi-
nant for overall outcome. Although surgical resection of
the tumor is occasionally possible, radiation therapy is
currently the standard treatment for this disease [2-6]. The
radiation therapy regimen includes external beam radia-
tion therapy (EBRT), brachytherapy, or a combination
thereof.
Brachytherapy has been shown to be an important com-
ponent of treatment in these patients. Treatment selection
can be adapted to account for stage and location of the
tumor. It can be done with either intracavitary or intersti-
tial approach. The majority of published studies with
interstitial brachytherapy have reported data using low-
dose-rate brachytherapy (LDRB) [2-9]. There have been
only few series using high-dose-rate brachytherapy
(HDRB) for vaginal tumors [10-12].
The purpose of this study was to evaluate the efficacy and
toxicities of HDRB for primary or recurrent vaginal cancer.
Methods
Between January 2000 and December 2006, 18 patients
with primary or recurrent vaginal cancer were treated with
HDRB. The median age was 69 yrs (range 43–88 yrs). Six
patients had primary vaginal cancer (stage II – 4 patients,
stage III – 1 patient and stage IV A – 1 patient). Twelve
patients were treated for isolated vaginal recurrence (pri-
mary cervix = 4, vulva = 1 and endometrium = 7). The
stage and grade (G) of endometrial cancer were IB G1-1
patient, IB G2-2 patients, IC G3-2 patient, IIA G 3 – 1
patient and IIB G2 – 1 patient. The median time to recur-
rence for all patients was 12 months (range 3 months – 18
years). Six of these patients had prior pelvic radiation ther-
apy. The type of previous radiation was EBRT alone 1
patient, EBRT plus brachytherapy 3 patients and brachy-
therapy alone 2 patients. The median time since previous
radiation to recurrence was 4 years (6 months – 18 years).
The recurrence was marginal (within 2 cm of previous
field) in 2 patients and within the previous field in 4
patients. The sites of disease were proximal vagina 9
patients, distal vagina 6 patients and diffuse disease in 3
patients.
All except one patient received a combination EBRT and
HDRB. The median dose of EBRT was 45 Gy (range
31.2–55.8 Gy) at 1.8 to 2 Gy per fraction. The technique
of EBRT was 3D conformal in 9 patients and IMRT in 8
patients. Five out of six patents with vaginal cancer also
had concurrent weekly cisplatinum at 40 mg/m2 along
with EBRT.
The HDRB was intracavitary brachytherapy for superfi-
cially invasive tumors (less than 5 mm of invasion), while
interstitial brachytherapy was used for more deeply inva-
sive tumors greater than 5 mm. Five patients had intracav-
itary brachytherapy utilizing Delclos Vaginal Applicators
system. Two of these patients had shielded vaginal appli-
cators to protect the uninvolved vaginal mucosa. Orthog-
onal X-ray films were obtained for planning and
verification of applicator placement. The median dose for
intracavitary brachytherapy was 20 Gy (12 – 20 Gy) in
3–5 fractions prescribed at 0.5 cm from the surface of the
applicator. One of these patients had intracavitary brach-
ytherapy only because of previous radiation therapy with
EBRT plus HDR brachytherapy. Interstitial brachytherapy
using a modified Syed-Nesblett template was performed
in 13 patients. We have previously described this tech-
nique [13]. In brief, the procedure was performed under
general anesthesia intra-operatively and epidural analge-
sia was used to control post-operative pain during the
course of treatment. Laparoscopic guidance was used for
tumors involving the vaginal apex to avoid injury to the
bladder or adjacent small bowel. CT simulation for inter-
stitial brachytherapy planning was performed and the
dose was prescribed to clinical target volume defined
based on clinical and imaging findings at the time of
implantation(Figure 1). Pretreatment clinical findings
and imaging were also taken for reference for defining the
target volume. The median number of needles used were
14 (range 7–18). The dose of interstitial brachytherapy
was 18.75 Gy in 5 fractions delivered twice daily.
The biologically equivalent dose (BED) in terms of equiv-
alent doses given at 2 Gy per day (EQ2) was calculated
using the LQ equation [14]. The α/β ratio was taken to be
10 Gy for tumor effects and 3 Gy for late effects. The
median EQ2 for the tumor was 66.48 Gy (31.25 – 75.4
Gy) for the entire group. The median EQ2 for the late
effects on vaginal mucosa was 75.71 Gy (55.99 – 105.99
Gy). The cumulative EQ2 for late effects on vaginal
mucosa for four patients who had prior overlapping field
radiation was 120.7 Gy, 130.31 Gy, 142.98 Gy and
154.54 Gy, respectively
The median follow-up was 18 months (range 6–66
months) for the entire group. Complete response (CR)
was achieved in all but one patient (94%). This one
patient with previous radiation therapy had recurrent pap-
illary serous endometrial cancer and had partial regres-
sion of the tumor. Of the 17 patients achieving a CR, 1
had local recurrence and 3 had systemic recurrence at a
median time of 6 months (range 6–22 months). The one
local recurrence was in the patient treated with previous
adjuvant radiation therapy for endometrioid adenocarci-
noma. Two patients have died of disease at 12 and 18
months, respectively. Both patients had recurrentRadiation Oncology 2008, 3:7 http://www.ro-journal.com/content/3/1/7
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Pre-RT MRI image (T1 with contrast) showing large vaginal cancer with extension to pelvic side wall and peri-urethral region Figure 1
Pre-RT MRI image (T1 with contrast) showing large vaginal cancer with extension to pelvic side wall and peri-
urethral region. Interstitial implantation showing coverage of clinical tumor volume (red) with isodose lines (100%-red, 90%-
blue, 75%-yellow, and 50% – green).Radiation Oncology 2008, 3:7 http://www.ro-journal.com/content/3/1/7
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endometrial cancer with papillary serous and carcinosar-
coma histology, respectively. Persistence of local disease
was noted in one of these patients. The 2-year actuarial
local control, cause-specific and overall survival for the
entire group was 88%, 82.5% and 78%, respectively. In
subset analysis, the crude local control was 6/6 (100%)
for primary vaginal cancer, 6/6 (100%) for the group with
recurrence without any prior radiation and 4/6 (67%) for
group with recurrence and any prior radiation therapy.
No grade 3 or worse early toxicity was observed. Two
patients had late grade 3 or 4 morbidity. One patient had
rectovaginal fistula 2 years after radiation therapy and
other patient had chronic vaginal ulcer with significant
narrowing and shortening of vagina (length of residual
vagina was about 2 cm). Both these patients had proximal
vaginal disease and had prior radiation therapy and their
EQ 2 for total doses were 142.98 Gy and 154 Gy, respec-
tively. The cumulative doses were highest in these two
patients. No other significant grade 3 or higher morbidity
was noted.
Discussion
Radiotherapy is the main therapeutic modality in the
management of primary or recurrent vaginal cancer.
Brachytherapy remains integral part of definitive radia-
tion therapy for these patients [2-9]. The preponderance
of the published literature on brachytherapy in this setting
demonstrates a wide variation on techniques and dose
utilized for LDRB. Although HDRB is widely available and
used for a variety of gynecologic malignancies, the pub-
lished data on this technique for vaginal cancer treatment
are limited. The HDR planning software offers the ability
to optimize the dwell time and position of the radioiso-
tope source (Ir-192) in order to create conformal radia-
tion treatment to a specified target. This improvement in
dose uniformity and ratios between tumor and normal
tissue is important advantage of HDR brachytherapy.
These advantages of HDRB over LDRB have to be weighed
against the need to use a larger number of HDR fractions
and the inconvenience of multiple implantations.
In a review of the literature regarding salvage treatment
options for vaginal recurrence, only two studies have
examined the efficacy of HDRB for treatment of vaginal
recurrences [11,15]. The study by Petignat, et al. on 22
patients with recurrent endometrial cancer reported local
tumor control rate and the 5-year disease-specific survival
rate of 100% and 96%, respectively [11]. Similarly, in the
series by Pai, et al. on 20 patients, 10-year local control
rate and disease-free survival rates were 74% and 46%,
respectively [15]. Our study with shorter follow-up shows
comparable local control and cause-specific survival. The
major difference between the published series and our
data is the technique of HDRB. The majority of the
patients in either study were treated with intracavitary
brachytherapy with only 2 patients having interstitial
implantation. In contrast, in our study 13/18 patients had
interstitial brachytherapy. The technique of intracavitary
is recommended for non-bulky recurrences (thickness < 5
mm after the completion of EBRT) while interstitial
brachytherapy is preferred approach for bulky recurrences
[16].
Interstitial brachytherapy has been traditionally per-
formed using LDRB techniques in this setting. Our tech-
nique involved one Syed-Neblett template implantation
procedure delivering 5 fractions twice a day for a total
HDRB dose of 18.75 Gy over 48 – 56 hours. Because of
lack of published data, the American Brachytherapy Soci-
ety (ABS) did not make any recommendation on HDRB
interstitial brachytherapy dose and fractionation schedule
for vaginal recurrences and preferred LDRB as the tech-
nique for interstitial brachytherapy [16]. Our treatment
regimen was well tolerated with excellent local control
and low toxicities in patients with no prior radiation.
Similarly, there are only few published studies on HDRB
for primary vaginal cancer. Kusher, et al. first reported on
19 patients treated with the combination of intracavitary
and interstitial brachytherapy [10]. The median HDRB
dose was 23 Gy (LDR equivalent of 29.8 Gy) after median
EBRT dose of 40 Gy. The 2-year progression-free survival
was 39.3% while the 2-year overall survival was 66.1%.
Three patients developed serious and/or late complica-
tions including urethral stenosis, painful vaginal necrosis
and small bowel obstruction of which two had interstitial
brachytherapy. The largest series of HDRB for vaginal can-
cer is from Vienna reporting on a total of 86 patients of
primary vaginal carcinoma treated with HDRB [12]. Early
stages of disease (stages 0–II) were treated with intravagi-
nal HDR brachytherapy alone (n  = 26/86), whereas
patients with locally advanced disease (stages II-IV)
received HDR brachytherapy combined with external
beam therapy (n = 55/86). The prescribed dose per frac-
tion varied from 5 Gy to 8 Gy, with a mean dose of 7 Gy.
In this large series only 8 patients had interstitial brachy-
therapy. The 5-year recurrence-free survival were 100%,
77%, 50%, 23%, and 0% for stage 0, I, II, III and IV respec-
tively. Chronic grade 1–4 side effects were observed in ≤
2% (bladder, rectum) and 1%–6% (vagina). Our series
only had 6 patients of primary vaginal cancer and all had
interstitial brachytherapy with 2-year local control of
100%. The toxicity profile was favorable with no grade 3
or higher toxicities.
In LDRB literature for vaginal cancer, an inverse relation-
ship between the total dose and rates of local recurrences
have been reported by several authors [17,18]. Chyle, et al.
noted an increasing risk of local recurrences in patientsRadiation Oncology 2008, 3:7 http://www.ro-journal.com/content/3/1/7
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who received <55 Gy when compared with those receiving
>55 Gy (53% vs. 17%) [12]. Similarly Fine, et al. reported
local failures in 25%, 33% and 62% of patients for the
administered dose of >75 Gy, 60–75 Gy and <60 Gy
respectively [18]. Our median EQ2 of 66.48 Gy is compa-
rable with these doses recommended in LDRB literature.
Besides, our calculation of biological equivalence is based
on the assumption of complete repair of sub-lethal radia-
tion damage between the two fractions [14]. With a twice-
daily (BID) fractionation schedule and time interval of 6
hours between fractionation, the sublethal damage may
not be complete thereby causing more injury to both
tumor and normal tissues than predicted by BED models.
Notwithstanding, our small series with preliminary
results shows that HDRB is efficacious for primary or
recurrent vaginal cancer. The fractionation schedule used
was well tolerated with a low incidence of acute or later
toxicities. Additional patients and follow-up are ongoing
to determine the long-term efficacy of this approach. The
limitation of our retrospective study is small size with lim-
ited follow up and heterogeneous patient population
evaluated (inclusion of both primary and recurrent dis-
ease). The incidence of primary or recurrent vaginal cancer
is low so that it is difficult for a single institution to have
a large series. That was the rationale to combine heteroge-
neous disease together to see the efficacy and toxicities of
this approach. As HDR equipment is widely available,
there are more institution doing HDR interstitial brachy-
therapy. We may need to consider multi-institutional
pooled analysis similar to the LDR experience [19] to see
the impact of this technique for local control and toxici-
ties and to define optimal fractionation schedules.
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